DTC wellness / supplements — UK
Ancient + Brave
A subscription wellness brand that has already fixed the thing most of its category gets wrong: the incentive tapers toward the list price instead of anchoring below it. The open question is the one underneath — the site quotes the discounted price everywhere and the list price almost nowhere, so the discipline is being exercised against a number the customer never sees.
This is not a leak-hunt. On the two questions that decide a subscription business — whether the incentive decays, and whether the product is worth returning to — the answers here are already good. What follows is about the next constraint rather than the last mistake.
Public signals read 19 August 2026. Every figure below is tagged with where it came from.
At a glance
- Company Observed
- MADE BY BRAVE LIMITED, inc. 2017Companies House 10778325The brand trades as Ancient + Brave; the registered entity carries a different name.
- Founded Observed
- Brand founded 2018 by Kate Princeancientandbrave.earth/pages/our-story; investor announcement, 2 Nov 2023
- Funding Observed
- £7m growth investment, November 2023Piper, “Our £7m investment in innovation-led wellness brand Ancient + Brave”, 2 Nov 2023
- Displayed price band Observed
- £17.60–£48.00ancientandbrave.earth product grid, 19 Aug 2026Every figure shown on the grid is the subscription price, not the list price.
- Subscription offer Observed
- 20% off the first three orders, 10% thereafterancientandbrave.earth product pages
- Customers claimed Observed
- “Trusted by over 600,000+ customers”ancientandbrave.earth homepage
- Turnover Observed
- Not disclosedCompanies House: accounts for a small company, y/e 31 Dec 2024The small-company regime files no profit and loss account.
Business model sketch
How this specific business makes money — read as a finance function would read it.
Ancient + Brave sells collagen and functional supplements direct to consumer — bovine and marine collagen peptides, creatine, magnesium, electrolytes, MCT oil, gut and protein blends — organised around daily rituals rather than ingredients. The registered entity is MADE BY BRAVE LIMITED, incorporated in 2017 and based in Lewes; the brand launched in 2018 and took a £7m growth investment in November 2023. It is a real, scaled operator with institutional capital behind it, and this analysis reads it as one.
The commercial model is subscription-first, and the shape of the incentive is the thing worth noticing. Subscribers get 20% off the first three orders and 10% on every order after that, with free UK delivery, skip-and-cancel-anytime terms and a refillable glass jar. That tapering matters more than it looks: most subscription offers in this category hold a single deep discount for ever, which permanently resets what the customer believes the product is worth. This one steps back toward the list price after the trial period, which is the correct instinct and is not common.
The cost base is loaded deliberately. The company is a certified B Corp, a member of 1% for the Planet, and — per its investor — a founding community member of ESGmark and certified Climate Neutral. Sourcing is specified: grass-fed EU bovine, MSC-certified wild-caught marine. There is an in-house Director of Nutrition & Education and a Director of Science & Innovation. None of that is decoration; all of it is margin spent on things that are supposed to hold the price up.
Acquisition runs through three visible routes: a product-recommendation quiz, a subscription incentive, and named personalities — an endorsement quote on the homepage and a co-branded ritual bundle carrying an ambassador’s name. Distribution extends beyond the site: at the time of the investment announcement the brand was stocked in more than 200 stores across 22 countries, including Selfridges, Harrods and Planet Organic. The tension worth the board’s attention is not that any of this is wrong. It is that the two strongest assets — a disciplined price ladder and a genuinely expensive cost base — are both currently invisible at the moment a customer decides.
Revenue driver reconstruction
The business as a system of levers — and which one actually binds.
Throughput
InferredSubscriber and order volumeNot disclosed; small-company accounts
Price
Observed£17.60–£48.00 displayed; £32.00 list on the flagshipancientandbrave.earth, 19 Aug 2026
Time
ObservedSubscription recurrence, 2–8 wkancientandbrave.earth delivery-frequency options
Result
RangeNot modelled — nothing filedThe small-company regime discloses no profit and loss account. Third-party commentary carries turnover and growth figures; none of it is filed, so none of it is asserted here.
Demand-constrained
A powder brand scales its logistics almost without limit, and a £7m raise removes working capital as the near-term ceiling. The binding constraint is retained demand at a defensible price: converting an incentivised first order into a subscription that survives the step from 20% to 10%, and then keeps surviving it. Everything commercially interesting sits on the retention-and-margin side, not the capacity side.
Sector economic model — UK DTC supplements & functional wellness
The analytical baseline we run every conversation in this sector against.
Typical revenue mix
- Subscription / recurring DTC35–55%
- One-off DTC purchase25–45%
- Retail / wholesale distribution10–25%
- Marketplace and international5–20%
Unit economics
- Category gross margin55–75%Inferred
- Steady-state subscriber discount10%Observed
- First-order discount norm in category20–40%Observed
- Subscription vs one-off LTV3–6× multipleRange
- Collagen as a traded inputCommodity — priced per kgInferred
How operators in this sector reach financeability
Route 1 — Subscription MRR
A low-churn subscriber base at a held margin is the asset an acquirer or lender underwrites, because it is the only line in a DTC brand that behaves like a contract. The tapering discount makes this route materially more credible here than it is for most of the category — provided the base survives the step-down rather than churning at it.
Route 2 — Retail and international distribution
Already in motion: 200+ stores across 22 countries at the time of the raise, including Selfridges and Harrods. Distribution converts brand into volume and validation, at the cost of margin and the direct customer relationship. The DTC base and its data are what earn favourable shelf terms rather than commodity ones.
Route 3 — Strategic acquisition
Acquisition by a larger wellness or FMCG group. The multiple turns on brand strength, retention curves and clean unit economics — and, increasingly, on certified sustainability credentials a corporate buyer can consolidate into its own reporting. The B Corp position is a genuine asset in that conversation, not a cost.
Common failure modes
- Reference-price drift — quoting the discounted price as the headline price everywhere, so the list price stops being believable.
- Churn at the step-down, when the subscriber discount narrows from the introductory rate to the standing one.
- Commoditisation — hydrolysed collagen is a traded input, so a premium defended only by trust is exposed to own-label and marketplace pricing.
- Range proliferation, where SKU count and format count grow faster than the ritual message that justified them.
- Concentration in borrowed audiences, whose cost, availability and renewal all sit outside the business.
- Regulatory tightening on health claims, which raises acquisition cost and caps what the product can say for itself.
Demand regime & elasticity
Why the intervention is trust and capture, not more traffic.
Classification: Considered on first purchase, habitual on repeat, and low switching cost throughout. A wellness supplement is bought on trust and evidence, then continued out of routine — which is why the category rewards retention architecture far more than it rewards acquisition spend, and why the first ninety days are worth more attention than the first click.
Information asymmetry
High — the buyer cannot verify quality
Out-of-pocket exposure
Low–Medium
Substitutability
High on paper, lower in practice
Urgency of need
Low
Identity / loyalty
High — mission and ritual-led
High information asymmetry is the defining feature and the commercial opportunity. A customer cannot tell hydrolysed collagen from hydrolysed collagen, which means the entire premium rests on evidence they are willing to accept rather than evidence they can check. That cuts both ways: it is why an undifferentiated competitor can undercut on price, and why a brand that makes its difference computable can hold a premium the competitor cannot follow.
Conditioning opportunity
The subscription programme is already the conditioning mechanism, and it is well built — tapering incentive, flexible intervals, refillable format, free gifts early in the journey. The unexploited part is tenure. The ladder currently runs downward and then flat: the best price a subscriber will ever see is in month one, and month thirty-six is worth exactly what month four was. A structure that pays for loyalty rather than only for arrival would turn the existing base into the predictable, financeable line the whole model is implicitly aiming at.
Observed commercial weaknesses
The evidence file. Each one is a recoverable opportunity, not a criticism.
| Observation | Likely commercial effect | Evidence |
|---|---|---|
| The displayed price is the discounted price | The single most consequential item, and the most easily fixed. Every figure on the product grid is the subscription price; the list price appears only inside the product page. So a brand that has earned the right to show a strong list price mostly does not show one — the discipline of stepping from 20% back to 10% is being measured against a number the customer has never seen, and a one-time buyer meets a price a quarter above the one they were quoted. | True Collagen displays “From: £25.60” on the grid; its product page shows £32.00 for a one-time purchase and £25.60 on subscription. The same pattern holds across the range.Observed |
| Acquisition leans on audiences the business does not own | The homepage leads on a named endorsement, and the co-branded ambassador bundle carries more customer ratings than the flagship product does. That is a strong signal the relationships are working. It also means a material share of demand is attached to people whose cost, availability and willingness to renew are decided outside the company, and it is the kind of dependency that is invisible until it is priced. | Homepage endorsement quote from a named public figure; the ambassador ritual bundle shows 8,223 ratings against 6,723 for the flagship collagen SKU.Observed |
| A widening range against a single-ritual proposition | Thirteen or more products across jar, multipack and sachet formats sit under a proposition built on one daily scoop. Breadth genuinely raises basket size and gives a subscriber somewhere to go next. It also multiplies stock complexity, spreads the evidence budget thinner across more claims, and makes the reason to subscribe harder to state in one sentence — which is the sentence the whole model rests on. | Product grid shows collagen in three types plus creatine, magnesium, hydration, biome, MCT, ancestral protein and a co-branded bundle, several in multiple formats.Observed |
| A deliberately expensive cost base the customer cannot compute | B Corp certification, 1% for the Planet, Climate Neutral, refillable glass, MSC-certified marine sourcing and an in-house science and nutrition function are all real carried cost, and all of it is spent defending a premium. But collagen is a commodity input priced per kilogram, and a buyer comparing two tubs cannot compute grams of specified active per pound. Until that comparison is made possible at the point of decision, the premium is held by trust alone — which works until a cheaper competitor borrows the same language. | Certifications and sourcing standards stated on the site and in the investor announcement; no price-per-serving or price-per-gram-of-active comparison observed at the point of purchase.Observed |
Competitor economic deconstruction
The whole board — and where each operator sits against the sector's anatomy.
| Dimension | Ancient + Brave | Funded DTC wellness peers | Own-label and marketplace |
|---|---|---|---|
| ModelInferred | Subscription-first DTC, plus premium retail | Subscription DTC, often marketing-led | One-off purchase, price-led |
| PositioningObserved | Certified sustainability, ritual, in-house science | Efficacy and range | Price and availability |
| Discount structureInferred | Tapering: 20% then 10% | Frequently a flat standing discount | Marketplace-driven |
| Cost baseInferred | Deliberately loaded — certification, sourcing, science staffing | Mixed | Minimised by design |
Ancient + Brave cannot win on price and should not try: its cost base is chosen, not inherited. What it can own is the one thing a price-led competitor structurally cannot copy — a verifiable, computable account of what the customer is actually buying, held up by certification a rival would have to spend years earning. The winnable game is not more customers. It is making the existing premium legible enough that the customer stops comparing it with the cheap tub, and then rewarding the ones who stay.
Risk matrix and enclosure
What to fence off, and the intervention that fences each one.
Reference-price risk
Subscription pricing shown as the headline figure across the product grid.
The list price stops functioning as an anchor, so the tapering ladder loses the effect it was designed to have and one-time buyers meet an unexplained uplift.
Price-presentation rebuild: show list and subscription together everywhere, so the discount reads as a saving rather than as the price.
Step-down churn risk
The subscriber discount narrows from 20% to 10% at the fourth order; no tenure reward observed beyond it.
Cohorts lapse at a predictable point in the lifecycle, before the acquisition cost of the incentivised first order has been recovered.
Build the ladder upward past the step-down — tenure rewards, replenishment timed to consumption, and a reason to be in year two that is not a price cut.
Audience-concentration risk
Ambassador bundle out-reviews the flagship; homepage led by a named endorsement.
Acquisition economics move with contracts and relationships the company does not control, and the dependency only becomes visible when one ends.
A first-party audience and content engine sized to carry acquisition on its own, with ambassador activity measured as incremental rather than assumed.
Commoditisation risk
Hydrolysed collagen is a traded input; no per-gram-of-active comparison surfaced at the point of purchase.
Own-label and marketplace competitors borrow the category language at a fraction of the price, and the premium is defended by trust rather than by arithmetic.
A computable-value layer: dose, specified active, provenance and cost per serving stated where the decision is made.
Entity and disclosure risk
The brand trades as Ancient + Brave through MADE BY BRAVE LIMITED, which files accounts for a small company and therefore publishes no profit and loss account, while third-party commentary carries turnover and growth figures.
Almost certainly an ordinary consequence of the filing regime rather than anything commercial — but it is the first thing a partner, lender or acquirer reconciles, and the reconciliation should exist before they ask.
Verification item — see below — resolved before any commercial conclusion is drawn from either source.
Intervention pathway
Each one traced to a costed leak or a named risk above.
Price-Presentation Rebuild
Layer 3Show the list price and the subscription price together on every surface a visitor sees, including the grid. This is first because it costs nothing, it is the root of the other pricing questions, and it is the only intervention here that makes work already done start paying.
Tenure & Lifecycle Engine
Layer 2Extend the ladder past the step-down: replenishment timed to actual consumption, rewards that grow with tenure rather than shrink, and a referral loop. Turns a subscription that currently pays best on day one into one that pays best in year two.
Computable-Value Layer
Layer 2Dose, specified active, sourcing standard and cost per serving, stated at the point of decision. Converts a premium currently held by trust into one held by arithmetic a competitor cannot match without matching the cost base.
Owned-Audience Content Engine
Layer 1A first-party audience and education operation carrying acquisition on its own, so ambassador and paid activity can be measured as incremental rather than depended on. The in-house nutrition and science function is the raw material; it is not currently working as an acquisition asset.
Indicative trajectory
Directional scenarios built on the inputs above. Not guarantees, not projections.
Conservative
Held reference price
first movement
Price presentation only. The list price becomes visible and believable, the tapering ladder starts reading as a saving, and margin per one-time order recovers with no change in volume.
With retention
Durable subscribers
compounding
Tenure architecture and lifecycle live. Cohorts survive the step from 20% to 10%, and the recurring base stops being a leaky introduction offer and starts being a contract.
With the data layer
Financeable base
structural
A segmented, retained, first-party subscriber base with clean unit economics and an acquisition engine it owns — the asset that decides the multiple in every one of the three financeability routes above.
Verification items
Open questions, not findings. Each is confirmed against internal data before any work begins.
- Turnover, order volume and active subscriber count — not disclosed under the small-company regime.
- Whether “600,000+ customers” counts retained customers, cumulative orders or site visitors, and how it reconciles with figures published elsewhere.
- Turnover and growth figures carried by third-party commentary, against what the filed small-company accounts disclose.
- Retention and churn curves either side of the fourth order, where the subscriber discount narrows.
- The commercial terms and measured incrementality of the ambassador and endorsement relationships.
- Whether the business trades through any entity other than MADE BY BRAVE LIMITED, and how the group is structured following the 2023 investment.
What this example demonstrates
Ancient + Brave is included because it is good. It has already done the two things this method usually has to argue for — an incentive that decays toward the real price, and a cost base spent on things that actually defend a premium — and it took institutional capital on the strength of them. The method is not only useful on businesses that are getting it wrong.
What it surfaces is a constraint rather than a leak: two of the brand’s strongest assets are invisible at the moment a customer decides. The price discipline is measured against a number the site does not show, and a genuinely expensive cost base is presented as values rather than as arithmetic. Nothing here needs more budget. It needs the work already done to be made visible. Every observation came from a public website, a free filing and the investor’s own announcement; the diagnostic phase is where the subscriber data establishes exactly what that invisibility is costing.
Built entirely from public signals — filed accounts, published pricing, and the company's own website as read on 19 August 2026. Figures are tagged Observed, Inferred or Range; ranges are conservative-to-realistic. Nothing here draws on internal data, and no commercial relationship exists between Axial Systems and Ancient + Brave. The diagnostic phase is what confirms each figure against a business's own numbers.
Run this diagnostic on your business.
The inputs are different. The method is the same. Your leakage profile will be specific to your numbers.